Audit of histomorphology and immunohistochemistry of the brain tumors: Revisited in context to the WHO 2016 molecular classification

Abstract

15defined and other medulloblastoma group is histologically defined.Addition of embryonal tumor multilayered rosettes C19MC altered, embryonal tumor with multilayered rosettes NOS, diffuse leptomeningeal glioneuronal tumors, anaplastic pleomorphic xanthoastrocytoma, and deleting some tumors such as primitive neuroectodermal tumors, gliomatosis cerebri, protoplasmic and fibrillary astrocytoma, cellular ependymoma. Another feature is the addition of brain invasion as a criterion for atypical meningiomas and introduction of grading system I, II, and III for hemangiopericytomas.A total of 150 brain tumors were retrospectively analyzed in this study. The histopathology was correlated with IHC findings to note the difference in result and correlate the histology with IHC, IDH and ATRX and 1p19 q by fluorescence in situ hybridization (FISH) in astrocytomas and oligodendrogliomas as elucidated earlier as IDH mutant then tested for 1p19q codeletion. Out of total 150 patients, 65 were males and 45 were females. Out of the 150 brain tumors the pre WHO 2016 diagnosis rendered were, 37 glial tumors in which there were 05 Grade 1 astrocytoma out which one was protoplasmic astrocytoma, 01 Grade 2 astrocytoma 05 anaplastic astrocytoma. 02 oligodendroglioma, 30 glioblastoma multiforme and one was gemistocytic glioblastoma, 02 mediastinal seminoma in ABSTRACT Background:The WHO 2016 molecular classification corroborating with the histology has given more significant diagnostic objectivity to the diagnosis of brain tumors and it is more reliable for instituting therapy as the heterogeneity and observer subjectivity are bypassed with the addition of isocitrate dehydrogenase, ATRX, and 1p19q, and other molecular markers. Aim: Our aim is to review the histopathology of diagnosed brain tumors and correlate with immunohistochemical (IHC) findings to note for any disparity to reform the diagnosis in order to benefit the patient and report to the clinician if any treatment change is to be considered. Materials and Methods: This article is based on studies of screening and diagnostic test. A total of 150 brain tumors were retrospectively analyzed. Age, gender, and the tumor histological type and grade were systematically recorded. We compared our histopathological diagnosis before the introduction of the WHO 2016 molecular classification of central nervous system tumors and later after the relevant IHC and fluorescence in situ hybridization studies. Statistical Analysis: The statistical analysis was done by using Statistical Package for Social Sciences version recent for Windows. Results: Out of the total 150 brain tumor patients, 65 were males and 45 were females. About 37 were glial and the rest were in other categories. Conclusions: The molecular diagnosis that substantiated with the histomorphology is more objective and beneficial in the treatment of the patients.